These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 19292062

  • 1. [A clinical trial for homoharringtonine and low-dose cytosine arabinoside combined with G-CSF or GM-CSF to treat the relapsed or refractory acute myeloid leukemia (AML), geriatric AML and advanced myelodysplastic syndromes].
    Xu J, Xu CG, Liu T, Xiang B, Chang H, He C.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jan; 40(1):129-32. PubMed ID: 19292062
    [Abstract] [Full Text] [Related]

  • 2. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
    Wu L, Li X, Su J, Chang C, He Q, Zhang X, Xu L, Song L, Pu Q.
    Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients.
    Li JM, Shen Y, Wu DP, Liang H, Jin J, Chen FY, Song YP, Song EY, Qiu XF, Hou M, Qiu ZC, Shen ZX.
    Int J Hematol; 2005 Jul; 82(1):48-54. PubMed ID: 16105759
    [Abstract] [Full Text] [Related]

  • 7. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.
    Zhang WG, Wang FX, Chen YX, Cao XM, He AL, Liu J, Ma XR, Zhao WH, Liu SH, Wang JL.
    Am J Hematol; 2008 Mar; 83(3):185-8. PubMed ID: 17899614
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS.
    Wu L, Li X, Su J, He Q, Zhang X, Chang C, Pu Q.
    J Cancer Res Clin Oncol; 2011 Oct; 137(10):1563-9. PubMed ID: 21845438
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.
    Becker PS, Medeiros BC, Stein AS, Othus M, Appelbaum FR, Forman SJ, Scott BL, Hendrie PC, Gardner KM, Pagel JM, Walter RB, Parks C, Wood BL, Abkowitz JL, Estey EH.
    Am J Hematol; 2015 Apr; 90(4):295-300. PubMed ID: 25545153
    [Abstract] [Full Text] [Related]

  • 13. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.
    Saito K, Nakamura Y, Aoyagi M, Waga K, Yamamoto K, Aoyagi A, Inoue F, Nakamura Y, Arai Y, Tadokoro J, Handa T, Tsurumi S, Arai H, Kawagoe Y, Gunnji H, Kitsukawa Y, Takahashi W, Furusawa S.
    Int J Hematol; 2000 Apr; 71(3):238-44. PubMed ID: 10846828
    [Abstract] [Full Text] [Related]

  • 14. Effect of granulocyte colony-stimulating factor priming combined with low-dose cytarabine and homoharringtonine in higher risk myelodysplastic syndrome patients.
    Wang FX, Zhang WG, He AL, Cao XM, Chen YX, Zhao WH, Yang Y, Wang JL, Zhang PY, Gu LF.
    Leuk Res; 2016 Sep; 48():57-61. PubMed ID: 27497340
    [Abstract] [Full Text] [Related]

  • 15. [Cohort Study on GHA and New Combined Priming Chemotherapeutic Regimens in Treatment of Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome].
    Ma XR, Wang J, Zhang WG, Chen YX, Cao XM, He AL, Liu J, Wang JL, Gu LF, Lei B, Zhang PY, Zhao WH, Yang Y, Wang FX, Xu Y.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Apr; 23(2):369-74. PubMed ID: 25948187
    [Abstract] [Full Text] [Related]

  • 16. [Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in MDS-EB and AML-MRC].
    Liu J, Jia JS, Gong LZ, Lu SY, Zhu HH, Huang XJ, Jiang H.
    Zhonghua Xue Ye Xue Za Zhi; 2018 Sep 14; 39(9):734-738. PubMed ID: 30369183
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
    Lee ST, Jang JH, Suh HC, Hahn JS, Ko YW, Min YH.
    Am J Hematol; 2001 Dec 14; 68(4):237-45. PubMed ID: 11754412
    [Abstract] [Full Text] [Related]

  • 19. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
    Gao S, Li Z, Fu JH, Hu XH, Xu Y, Jin ZM, Tang XW, Han Y, Chen SN, Sun AN, Wu DP, Qiu HY.
    Asian Pac J Cancer Prev; 2015 Dec 14; 16(15):6627-32. PubMed ID: 26434886
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study.
    Wu L, Li X, Chang C, Xu F, He Q, Wu D, Zhang Z, Su J, Zhou L, Song L, Chao X, Zhao Y.
    Leuk Lymphoma; 2016 Dec 14; 57(6):1367-74. PubMed ID: 26397697
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.